Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors

Manjula Shantaram, Anjali Rao, Annaya Rao Aroor, Annaswamy Raja, Suryanrayana Rao, Flama Monteiro

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression. The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors. But there are very few reports available on the serum glycoconjugate levels in patients with brain tumors. Objective: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients. Materials and Methods: Colorimetric estimation of TSA using diphenylamine was done on 100 patients with intracranial tumors; follow-up study was carried out in 24 cases. The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients. The various types of brain tumors included in this study were glioma, meningioma, and acoustic neurinoma as well as some other types such as medulloblastoma, secondary tumors, and craniopharyngioma. Results: There was no significant difference between the TSA and LBSA concentrations seen in pretreatment or post-treatment cases and that seen in control subjects. Discussion: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors. TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

Original languageEnglish
Pages (from-to)162-166
Number of pages5
JournalAnnals of Indian Academy of Neurology
Volume12
Issue number3
DOIs
Publication statusPublished - 01-07-2009
Externally publishedYes

Fingerprint

N-Acetylneuraminic Acid
Brain Neoplasms
Lipids
Glycoconjugates
Tumor Biomarkers
Serum
Phosphotungstic Acid
Diphenylamine
Craniopharyngioma
Neoplasms
Medulloblastoma
Acoustic Neuroma
Meningioma
Glioma
Cerebrospinal Fluid
Cell Membrane

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Shantaram, Manjula ; Rao, Anjali ; Aroor, Annaya Rao ; Raja, Annaswamy ; Rao, Suryanrayana ; Monteiro, Flama. / Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. In: Annals of Indian Academy of Neurology. 2009 ; Vol. 12, No. 3. pp. 162-166.
@article{28bd32d73aac47699715e0c4ca22e563,
title = "Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors",
abstract = "Background: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression. The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors. But there are very few reports available on the serum glycoconjugate levels in patients with brain tumors. Objective: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients. Materials and Methods: Colorimetric estimation of TSA using diphenylamine was done on 100 patients with intracranial tumors; follow-up study was carried out in 24 cases. The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients. The various types of brain tumors included in this study were glioma, meningioma, and acoustic neurinoma as well as some other types such as medulloblastoma, secondary tumors, and craniopharyngioma. Results: There was no significant difference between the TSA and LBSA concentrations seen in pretreatment or post-treatment cases and that seen in control subjects. Discussion: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors. TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.",
author = "Manjula Shantaram and Anjali Rao and Aroor, {Annaya Rao} and Annaswamy Raja and Suryanrayana Rao and Flama Monteiro",
year = "2009",
month = "7",
day = "1",
doi = "10.4103/0972-2327.56315",
language = "English",
volume = "12",
pages = "162--166",
journal = "Annals of Indian Academy of Neurology",
issn = "0972-2327",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. / Shantaram, Manjula; Rao, Anjali; Aroor, Annaya Rao; Raja, Annaswamy; Rao, Suryanrayana; Monteiro, Flama.

In: Annals of Indian Academy of Neurology, Vol. 12, No. 3, 01.07.2009, p. 162-166.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors

AU - Shantaram, Manjula

AU - Rao, Anjali

AU - Aroor, Annaya Rao

AU - Raja, Annaswamy

AU - Rao, Suryanrayana

AU - Monteiro, Flama

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Background: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression. The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors. But there are very few reports available on the serum glycoconjugate levels in patients with brain tumors. Objective: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients. Materials and Methods: Colorimetric estimation of TSA using diphenylamine was done on 100 patients with intracranial tumors; follow-up study was carried out in 24 cases. The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients. The various types of brain tumors included in this study were glioma, meningioma, and acoustic neurinoma as well as some other types such as medulloblastoma, secondary tumors, and craniopharyngioma. Results: There was no significant difference between the TSA and LBSA concentrations seen in pretreatment or post-treatment cases and that seen in control subjects. Discussion: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors. TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

AB - Background: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression. The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors. But there are very few reports available on the serum glycoconjugate levels in patients with brain tumors. Objective: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients. Materials and Methods: Colorimetric estimation of TSA using diphenylamine was done on 100 patients with intracranial tumors; follow-up study was carried out in 24 cases. The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients. The various types of brain tumors included in this study were glioma, meningioma, and acoustic neurinoma as well as some other types such as medulloblastoma, secondary tumors, and craniopharyngioma. Results: There was no significant difference between the TSA and LBSA concentrations seen in pretreatment or post-treatment cases and that seen in control subjects. Discussion: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors. TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=70350123895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350123895&partnerID=8YFLogxK

U2 - 10.4103/0972-2327.56315

DO - 10.4103/0972-2327.56315

M3 - Article

VL - 12

SP - 162

EP - 166

JO - Annals of Indian Academy of Neurology

JF - Annals of Indian Academy of Neurology

SN - 0972-2327

IS - 3

ER -